<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CEBD0459-3618-46C0-981C-734AAAABCE4B"><gtr:id>CEBD0459-3618-46C0-981C-734AAAABCE4B</gtr:id><gtr:name>MRC Mammalian Genetics Unit</gtr:name><gtr:address><gtr:line1>Harwell</gtr:line1><gtr:line4>Didcot</gtr:line4><gtr:line5>Oxfordshire</gtr:line5><gtr:postCode>OX11 0RD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CEBD0459-3618-46C0-981C-734AAAABCE4B"><gtr:id>CEBD0459-3618-46C0-981C-734AAAABCE4B</gtr:id><gtr:name>MRC Mammalian Genetics Unit</gtr:name><gtr:address><gtr:line1>Harwell</gtr:line1><gtr:line4>Didcot</gtr:line4><gtr:line5>Oxfordshire</gtr:line5><gtr:postCode>OX11 0RD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ECC976E7-B6C0-415D-A8FA-FCBF275E7D27"><gtr:id>ECC976E7-B6C0-415D-A8FA-FCBF275E7D27</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7AC97265-961F-4138-8168-0DC7443F90F3"><gtr:id>7AC97265-961F-4138-8168-0DC7443F90F3</gtr:id><gtr:firstName>Abraham</gtr:firstName><gtr:surname>Acevedo-Arozena</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_A390_1106"><gtr:id>64552610-FDC4-4CBB-9654-24C7B0489967</gtr:id><gtr:title>Neurodegeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_A390_1106</gtr:grantReference><gtr:abstractText>Our major aim is to identify new genes or genetic pathways involved in neurodegeneration and try to understand how these genetic mutations lead to disease using mouse models.
Once a human genetic mutation is identified that is causative for a disorder, the next step in most investigations of disease mechanisms (and therefore in developing therapeutics) is to make mouse models of the genetic disorder, such that we can then investigate every stage of pathogenesis in all tissues. This is critically important for neurodegeneration, where interactions between different neuronal populations and other cells in the brain and spinal cord cannot be recapitulated in vitro. 
We focus our work mainly on Amyotrophic lateral sclerosis (ALS) and Huntington?s disease (HD). They are both fatal neurodegenerative disorders for which no major treatments exist. The focus of our work is twofold. First, we work on new disease causative genes identified by others and develop new mouse models carrying mutations on those genes with the ultimate aim of understanding how these mutations lead to neurodegeneration at the cellular and molecular level. Second, we identify new genes involved in neurodegeneration in the mouse by using mutagenesis. The mutagenesis consist of mutating genes in the mouse and then study the mutant mice over time for any neurodegenerative disease symptoms, such as muscle weakness or motor disturbances such as tremors or gait abnormalities. 
All new mouse models identified are made freely available to the scientific community.</gtr:abstractText><gtr:technicalSummary>Our major aim is to identify and elaborate new genetic pathways involved in neurodegeneration using disease mouse models. In particular, we focus our work on two major neurodegenerative disorders: Huntington?s disease (HD) and Amyotrophic lateral sclerosis (ALS). Despite intense research focus on HD and ALS, they both remain incurable, and the only available treatment licensed for ALS, Riluzole, has limited therapeutic benefits. Although both disorders are very different in their genetics, they are both fatal and exemplify the need for a deeper understanding of disease pathogenesis as the base on which to build the search for therapeutic intervention. 
Mouse models are critical in our current understanding of disease processes, including neurodegeneration. The focus of our programme is to elaborate on disease pathogenesis by studying neurodegeneration mouse models. We work with both established neurodegeneration mouse models as well as generating our own new mouse models, making them immediately available to the research community. We uncover new genes and mechanisms leading to neurodegeneration by means of two major methodologies: First, the generation of new disease mouse models carrying point mutations in known neurodegenerative causative genes, their behavioural characterisation and the subsequent elucidation of the molecular mechanisms leading to disease. We are currently focussing on ALS genes using this approach, and have uncovered new ALS mouse models carrying point mutations in Sod1 and Tardbp (the gene encoding TDP43). Second, the identification of new genes involved in neurodegeneration by means of ENU mutagenesis forward genetics screening. The screening pipelines used include modifier screens over well established disease mouse models (both HD and ALS models) as well as the identification of new neurodegenerative genes through the Harwell ENU ageing screen pipeline. 
Our genetic work is set in the context of our key links into other leading UK laboratories bringing genetic, biochemical and cell biological studies to bear. The new mouse models provided, together with the new disease pathways identified would be valuable tools in the further elucidation of neurodegeneration pathophysiology by us and others.</gtr:technicalSummary><gtr:fund><gtr:end>2016-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1903758</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminar Sussex University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>400DD116-000B-49EF-BB6C-4B2B70B83481</gtr:id><gtr:impact>Neuroscience Department seminar

Collaborative work with Dr Majid Hafezparast</gtr:impact><gtr:outcomeId>5453a3106411c0.05209511</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxfordshire Science Festival-Bonn Square, Oxford</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>46CA81E8-CE7C-439D-B68D-5FEAA5162162</gtr:id><gtr:impact>MRC stand on Oxfordshire Science Festival-Bonn Square, Oxford: Brain and neurodegeneration

Increase interest from members of the public, particulary children, on research into neurodegeneration</gtr:impact><gtr:outcomeId>5453a4ad394f93.69724312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>93098080-D64A-4DB2-9FED-A798029225BA</gtr:id><gtr:impact>Participation, via a member of the group (Dr Alison Landman) on the MRC Harwell stand and the Cheltenham Science Festival

Good response from general members of the public</gtr:impact><gtr:outcomeId>5453a3d7af9416.66820022</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AF099B51-2274-49B1-A8D4-B2ED9C66D314</gtr:id><gtr:impact>BBC website documentary on mouse research

Not aware of any impact</gtr:impact><gtr:outcomeId>544f811fa20aa8.46267383</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-26255305</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Seminar Madrid, SIlvia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A082F96D-456D-41A2-AF25-7E08C5F94A96</gtr:id><gtr:impact>Seminar in Madrid on our work on Huntington's disease modifiers

To inform of our research results internationally and to establish new collaborators</gtr:impact><gtr:outcomeId>5453a527e93262.31141274</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC careers workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2DBB5D50-83F0-40E7-B3FC-793492BD38F0</gtr:id><gtr:impact>Talk by Silvia Corrochano, a member of the work, on the 2014 Science career workshop by the MRC

MRC headoffice made aware of the difficulties to make the transition between post-doctoral researcher and junior group leader</gtr:impact><gtr:outcomeId>5453a5cdeab7f2.96914012</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>112690</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Motor Neurone Disease Association Studentship</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>04B5107D-C8C9-4D84-A298-3824B089503D</gtr:id><gtr:outcomeId>544f7e568e8863.02122938</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>88690</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Motor Neurone Disease Association PhD studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>8BF74E95-F8FD-4D43-8082-DBF1577BC9FE</gtr:id><gtr:outcomeId>56dd5be67a5776.42116439</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Charity visit for the Concordat on Openness on Animal Research</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4330BCCA-665A-44DC-8FCF-1DE8655D799C</gtr:id><gtr:outcomeId>5452642dde5421.60585051</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new mouse model of myotonia and periodic paralysis carrying a novel point mutation in the gene Scn4a</gtr:description><gtr:id>F33B56CB-DF9F-44DD-95F4-9F9C353899A8</gtr:id><gtr:impact>Just published</gtr:impact><gtr:outcomeId>544f81d1a1baf7.65652425</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mouse model for myotonia and periodic paralysis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D8EDFB6D-78EA-469D-A079-A157E1E19BBB</gtr:id><gtr:title>Novel gene function revealed by mouse mutagenesis screens for models of age-related disease.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84a6f54d416548b39d265a48e739e157"><gtr:id>84a6f54d416548b39d265a48e739e157</gtr:id><gtr:otherNames>Potter PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58bd3b49797524.38938073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6C3693F-84E3-442A-9B2B-39F31D56B90E</gtr:id><gtr:title>Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae312a95b658688d9e502f838b047b75"><gtr:id>ae312a95b658688d9e502f838b047b75</gtr:id><gtr:otherNames>Corrochano S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544f78bfd0c195.79279607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C2DCC00-600D-431F-B57B-F769D3C0437D</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>56dd5961966463.94162175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C8BFCF5-EC18-4A8D-86C1-A4274E1C5D0B</gtr:id><gtr:title>Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae312a95b658688d9e502f838b047b75"><gtr:id>ae312a95b658688d9e502f838b047b75</gtr:id><gtr:otherNames>Corrochano S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>544f7a28b78688.82979764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2A8FBF2-2413-4F3B-813F-9D42F7BAD080</gtr:id><gtr:title>Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3b1f101fc39803c11f89c7209db490"><gtr:id>8b3b1f101fc39803c11f89c7209db490</gtr:id><gtr:otherNames>Cortese A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>544f79527ac816.39731982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>595F0399-345A-4D94-8BC1-F3D2EF71CC70</gtr:id><gtr:title>Analysis of Individual Mouse Activity in Group Housed Animals of Different Inbred Strains using a Novel Automated Home Cage Analysis System.</gtr:title><gtr:parentPublicationTitle>Frontiers in behavioral neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02615f8e9fa8be2afebebd42f096d9d0"><gtr:id>02615f8e9fa8be2afebebd42f096d9d0</gtr:id><gtr:otherNames>Bains RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1662-5153</gtr:issn><gtr:outcomeId>585d404777f845.33185884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B3C3BB8-EEA5-4152-936C-4A45D8683308</gtr:id><gtr:title>A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56dd596156dc92.70040199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A9348AC-DAD3-4479-A797-207B0ADDC602</gtr:id><gtr:title>Loss-of-Function Mutations in FRRS1L Lead to an Epileptic-Dyskinetic Encephalopathy.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cbecc303d2e334d5905d7f14159341e"><gtr:id>7cbecc303d2e334d5905d7f14159341e</gtr:id><gtr:otherNames>Madeo M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58bd3b49373ac9.93018751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F42F51-06C4-4CC5-A5ED-406ABC73303F</gtr:id><gtr:title>Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccd7dfc8b2f380f88687cbf25b84d0f2"><gtr:id>ccd7dfc8b2f380f88687cbf25b84d0f2</gtr:id><gtr:otherNames>Joyce PI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>585d55488aac98.04949433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>599DCF89-7AAD-4FE3-8CA1-9F01BCEB99BF</gtr:id><gtr:title>A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity and causes limb-clasping and body tone defects.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/311b04aa4c17b316103c9775174f68e9"><gtr:id>311b04aa4c17b316103c9775174f68e9</gtr:id><gtr:otherNames>Ricketts T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544f78e56eda79.14491809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BC4905B-1A0A-48B0-8438-16FB46661B2E</gtr:id><gtr:title>Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in 'FUSDelta14' knockin mice.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c5f2caa31f81dc3dd97e3cb514bba47"><gtr:id>4c5f2caa31f81dc3dd97e3cb514bba47</gtr:id><gtr:otherNames>Devoy A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a953bf6dede14.47253879</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_A390_1106</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>